Benefits in the lipid profile after substitution of abacavir for stavudine:: A 48-week prospective study

被引：8

作者：

García-Benayas, T

Blanco, F

Alcolea, A

De la Cruz, JJ

González-Lahoz, J

Soriano, V

机构：

[1] Hosp Carlos III, Infect Dis Serv, Madrid 28035, Spain

[2] Univ Autonoma Madrid, Dept Prevent Med & Publ Hlth, Madrid, Spain

来源：

AIDS RESEARCH AND HUMAN RETROVIRUSES | 2004年 / 20卷 / 12期

关键词：

D O I：

10.1089/aid.2004.20.1289

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Stavudine (d4T) has been associated with lipoatrophy and hyperlactatemia. In recent studies, d4T has also been related to both hypercholesterolemia and hypertriglyceridemia. Replacing d4T with another nucleoside analogue such as abacavir (ABC) may reduce lactate levels and improve lipoatrophy in the long term. However, the impact of this strategy on the lipid profile is still unclear. In a prospective and randomized study, fasting lipids were examined over 48 weeks in 112 subjects on d4T regimens, 49 of whom replaced d4T with ABC. The substitution of ABC for d4T was found to be safe and provided a reduction in both LDL cholesterol and the total cholesterol (TC)/HDLc ratio, which might impact favorably on cardiovascular risk.

引用

页码：1289 / 1292

页数：4

共 14 条

[1] Hydroxyurea plus didanosine as maintenance therapy for HIV-infected patients on long-term successful highly active antiretroviral therapy [J].

Barreiro, P ;

de Mendoza, C ;

Camino, N ;

García-Benayas, T ;

Blanco, F ;

Núñez, M ;

González-Lahoz, J ;

Soriano, V .

HIV CLINICAL TRIALS, 2003, 4 (06) :361-371

[2] Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy [J].

Brinkman, K ;

Smeitink, JA ;

Romijn, JA ;

Reiss, P .

LANCET, 1999, 354 (9184) :1112-1115

[3] An objective case definition of lipodystrophy in HIV-infected adults: a case-control study [J].

Carr, A ;

Emery, S ;

Law, I ;

Puls, R ;

Lundgren, JD ;

Powderly, WG ;

Carr, B ;

Cooper, DA ;

Grinspoon, S ;

Ioannidis, J ;

Lewis, R ;

Law, M ;

Lichtenstein, K ;

Murray, J ;

Pizzuti, D ;

Rozenbaum, W ;

Schambelan, M ;

Moore, A ;

Miller, J .

LANCET, 2003, 361 (9359) :726-735

[4] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].

Cleeman, JI ;

Grundy, SM ;

Becker, D ;

Clark, LT ;

Cooper, RS ;

Denke, MA ;

Howard, WJ ;

Hunninghake, DB ;

Illingworth, DR ;

Luepker, RV ;

McBride, P ;

McKenney, JM ;

Pasternak, RC ;

Stone, NJ ;

Van Horn, L ;

Brewer, HB ;

Ernst, ND ;

Gordon, D ;

Levy, D ;

Rifkind, B ;

Rossouw, JE ;

Savage, P ;

Haffner, SM ;

Orloff, DG ;

Proschan, MA ;

Schwartz, JS ;

Sempos, CT ;

Shero, ST ;

Murray, EZ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497

[5]

DOMINGO P, 2003, 9 EUR AIDS C WARS OC

[6] Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy:: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group [J].

Dubé, MP ;

Stein, JH ;

Aberg, JA ;

Fichtenbaum, CJ ;

Gerber, JG ;

Tashima, KT ;

Henry, WK ;

Currier, JS ;

Sprecher, D ;

Glesby, MJ .

CLINICAL INFECTIOUS DISEASES, 2003, 37 (05) :613-627

[7] Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study [J].

Fellay, J ;

Boubaker, K ;

Ledergerber, B ;

Bernasconi, E ;

Furrer, H ;

Battegay, M ;

Hirschel, B ;

Vernazza, P ;

Francioli, P ;

Greub, G ;

Flepp, M ;

Telenti, A .

LANCET, 2001, 358 (9290) :1322-1327

[8] Combination antiretroviral therapy and the risk of myocardial infarction [J].

Friis-Moller, N ;

Sabin, CA ;

Weber, R ;

Monforte, AD ;

El-Sadr, WM ;

Reiss, P ;

Thiébaut, R ;

Morfeldt, L ;

De Wit, S ;

Pradier, C ;

Calvo, G ;

Law, MG ;

Kirk, O ;

Phillips, AN ;

Lundgren, JD ;

Weber, R ;

Monteforte, AD ;

Bartsch, G ;

Reiss, P ;

Dabis, F ;

Morfeldt, L ;

De Wit, S ;

Pradier, C ;

Calvo, G ;

Law, MG ;

Kirk, O ;

Phillips, AN ;

Houyez, F ;

Loeliger, E ;

Tressler, R ;

Weller, I ;

Friis-Moller, N ;

Sabin, CA ;

Sjol, A ;

Lundgren, JD ;

Sawitz, A ;

Rickenbach, M ;

Pezzotti, P ;

Krum, E ;

Meester, R ;

Lavignolle, V ;

Sundström, A ;

Poll, B ;

Fontas, E ;

Torres, F ;

Petoumenos, K ;

Kjær, J ;

Hammer, S ;

Neaton, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (21) :1993-2003

[9] Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy [J].

García-Benayas, T ;

Blanco, F ;

de la Cruz, JJ ;

Soriano, V ;

González-Lahoz, J .

AIDS, 2003, 17 (06) :921-924

[10] Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients [J].

John, M ;

McKinnon, EJ ;

James, IR ;

Nolan, DA ;

Herrmann, SE ;

Moore, CB ;

White, AJ ;

Mallal, SA .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 33 (01) :29-33

← 1 2 →